HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2007-1073v1 26/12/3027    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eyler, C. E. Articles by Rich, J. N. Search for Related Content PubMed PubMed Citation Articles by Eyler, C. E. Articles by Rich, J. N.

CANCER STEM CELLS

Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition

^aSchool of Medicine,
Departments of ^bPharmacology and Cancer Biology,
^dPathology,
^eSurgery, and
^fMedicine, and
^cPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham North Carolina, USA;
^gDepartment of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, Ohio, USA

Key Words. Glioma • Akt • Targeted therapy • Small molecule inhibitor • Cancer stem cell

Correspondence: Correspondence: Jeremy N. Rich, M.D., Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE30, Cleveland, Ohio 44195, USA. Telephone: 919-684-0081; Fax: 919-684-6514; e-mail: richj{at}ccf.org

Received on December 17, 2007; accepted for publication on September 8, 2008.

First published online in STEM CELLS EXPRESS  September 18, 2008.

Malignant brain tumors are among the most lethal cancers, and conventional therapies are largely limited to palliation. Novel therapies targeted against specific molecular pathways may offer superior efficacy and less toxicity than conventional therapies, but initial clinical trials of molecular targeted agents in brain cancer therapy have been frequently disappointing. In brain tumors and other cancers, subpopulations of tumor cells have recently been characterized by their ability to self-renew and initiate tumors. Although these cancer stem cells, or tumor initiating cells, are often only present in small numbers in human tumors, mounting evidence suggests that cancer stem cells contribute to tumor maintenance and therapeutic resistance. Thus, the development of therapies that target cancer stem cell signal transduction and biology may improve brain tumor patient survival. We now demonstrate that populations enriched for cancer stem cells are preferentially sensitive to an inhibitor of Akt, a prominent cell survival and invasion signaling node. Treatment with an Akt inhibitor more potently reduced the numbers of viable brain cancer stem cells relative to matched nonstem cancer cells associated with a preferential induction of apoptosis and a suppression of neurosphere formation. Akt inhibition also reduced the motility and invasiveness of all tumor cells but had a greater impact on cancer stem cell behaviors. Furthermore, inhibition of Akt activity in cancer stem cells increased the survival of immunocompromised mice bearing human glioma xenografts in vivo. Together, these results suggest that Akt inhibitors may function as effective anticancer stem cell therapies.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				J. M. Rosen and C. T. Jordan The Increasing Complexity of the Cancer Stem Cell Paradigm Science, June 26, 2009; 324(5935): 1670 - 1673. [Abstract] [Full Text] [PDF]

				Z. Li, H. Wang, C. E. Eyler, A. B. Hjelmeland, and J. N. Rich Turning Cancer Stem Cells Inside Out: An Exploration of Glioma Stem Cell Signaling Pathways J. Biol. Chem., June 19, 2009; 284(25): 16705 - 16709. [Abstract] [Full Text] [PDF]

				J.N. Rich and C.E. Eyler Cancer Stem Cells in Brain Tumor Biology Cold Spring Harb Symp Quant Biol, March 27, 2009; (2009) sqb.2008.73.060v1. [Abstract] [PDF]